NCT00570336 - Study of CTS-1027 in Hepatitis C Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions

Chronic Hepatitis C Virus Infection

Interventions

DRUG

CTS-1027

Eligible patients were randomized to one of four doses of CTS-1027 (2.5 mg, 5 mg, 10 mg, or 30 mg) or placebo qd (quaque die, once daily).

OTHER

Placebo

Eligible patients were randomized to one of four doses of CTS-1027 (2.5 mg, 5 mg, 10 mg, or 30 mg) or placebo qd.

Trial Locations (19)

10019

Mt. Sinai School of Medicine, New York

10468

Bronx VA Medical Center, The Bronx

23249

McGuire Hospital DVAMC, Richmond

27710

Duke University Medical Center, Durham

30309

Digestive Healthcare of Georgia, Atlanta

33136

University of Miami, Miami

35233

University of Alabama at Birmingham, Birmingham

44195

Cleveland Clinic, Cleveland

45219

Consultants of Clinical Research, Cincinnati

48322

Henry Ford Health System, West Bloomfield

55905

Mayo Clinic, Rochester

70112

Tulane University Health Sciences Center, New Orleans

77030

Advanced Liver Therapies - Baylor College of Medicine, Houston

VAMC - Baylor College of Medicine, Houston

80045

University of Colorado Denver, Aurora

92037

Scripps Clinic, La Jolla

92154

Kaiser Permanente, San Diego

94115

California Pacific Medical Center, San Francisco

02215

Beth Israel Deaconess Medical Center, Boston